GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

Leading industry experts join the Vertex Chief Strategy Office to shape product innovation and strengthen global compliance ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. The company is also poised to benefit from two ...